pharmaphorum September 18, 2024
Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk’s obesity drug semaglutide to make the drug more accessible to consumers in the US.
The bold move has been accompanied by a full-page ad in the Wall Street Journal explaining its reasoning, and claiming that the prices of GLP-1 drugs for weight loss are five times too high and need to be brought in line with levels in other countries.
Compounded versions of drugs can be made available to people in the US under regulations that facilitate access to drugs that are in short supply. That means compounded versions of semaglutide – the active ingredient in Novo Nordisk’s Ozempic and Rybelsus for diabetes and obesity therapy Wegovy...
Today's Sponsors
Today's Sponsor